EA201691660A1 - Применение обратно-мицеллярных систем для осуществления доставки хелатирующих агентов радионуклидов и металлов - Google Patents

Применение обратно-мицеллярных систем для осуществления доставки хелатирующих агентов радионуклидов и металлов

Info

Publication number
EA201691660A1
EA201691660A1 EA201691660A EA201691660A EA201691660A1 EA 201691660 A1 EA201691660 A1 EA 201691660A1 EA 201691660 A EA201691660 A EA 201691660A EA 201691660 A EA201691660 A EA 201691660A EA 201691660 A1 EA201691660 A1 EA 201691660A1
Authority
EA
Eurasian Patent Office
Prior art keywords
reverse
micellar systems
radionuclides
metals
delivery
Prior art date
Application number
EA201691660A
Other languages
English (en)
Other versions
EA037605B1 (ru
Inventor
Карилин Боэр
Элза Компт
Оливье Греми
Лоран Микколи
Хайме Франсиско Ангуло-Мора
Жан-Клод Морель
Original Assignee
Медзис Фарма
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медзис Фарма filed Critical Медзис Фарма
Publication of EA201691660A1 publication Critical patent/EA201691660A1/ru
Publication of EA037605B1 publication Critical patent/EA037605B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A61K47/6909—Micelles formed by phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1809—Micelles, e.g. phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Abstract

Настоящее изобретение относится к обратно-мицеллярным системам, содержащим, по меньшей мере, активный реагент, ацилглицерин, стерол, лецитин, этанол и воду, предназначенным для применения в хелатировании и/или связывании в комплекс радионуклида и/или металла в организме пациента. Изобретение также относится к обратно-мицеллярным системам и фармацевтическим композициям, включающим в себя упомянутые обратно-мицеллярные системы.
EA201691660A 2014-02-18 2015-02-17 Применение обратно-мицеллярных систем для доставки реагентов, хелатирующих радионуклиды и металлы EA037605B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305217 2014-02-18
PCT/EP2015/053339 WO2015124581A1 (en) 2014-02-18 2015-02-17 Use of a reverse-micellar system for delivering chelators of radionuclides and metals

Publications (2)

Publication Number Publication Date
EA201691660A1 true EA201691660A1 (ru) 2017-01-30
EA037605B1 EA037605B1 (ru) 2021-04-20

Family

ID=50231093

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691660A EA037605B1 (ru) 2014-02-18 2015-02-17 Применение обратно-мицеллярных систем для доставки реагентов, хелатирующих радионуклиды и металлы

Country Status (10)

Country Link
US (2) US10172954B2 (ru)
EP (1) EP3107580B1 (ru)
JP (1) JP6649262B2 (ru)
KR (1) KR102392454B1 (ru)
CN (1) CN106163571B (ru)
AU (1) AU2015220878B2 (ru)
CA (1) CA2939760C (ru)
EA (1) EA037605B1 (ru)
IL (1) IL247253B (ru)
WO (1) WO2015124581A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890255A1 (ru) * 2015-07-09 2018-07-31 Медзис Фарма Приготовление цианомостиковых металлических наночастиц в биосовместимой обращенной мицеллярной системе in situ
CA3103704A1 (en) 2018-07-06 2020-01-09 Medesis Pharma Treatment and prevention of injury due to radiation exposure
KR20210065968A (ko) * 2018-09-20 2021-06-04 타우토나 그룹 아이피 홀딩 컴퍼니 엘엘씨 심미적 피부 상태를 치료하기 위한 철 킬레이팅 화합물
CN111282064A (zh) * 2020-02-21 2020-06-16 中国人民解放军陆军军医大学第一附属医院 ZnNa3-DTPA螯合树脂及其在去除放射性核素的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61204137A (ja) * 1985-03-06 1986-09-10 Yutaka Mizushima 放射性造影剤
US5807527A (en) * 1991-05-29 1998-09-15 Flinders Technologies Pty. Ltd. Solid medium and method for DNA storage
HUT77553A (hu) * 1994-11-30 1998-05-28 Schering Aktiengesellschaft Eljárás fémeket tartalmazó kelát komplexek alkalmazására a máj és az epe röntgendiagnosztikájában
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
WO2005089412A2 (en) * 2004-03-17 2005-09-29 Takemoto Arnold C Tissue detoxification and health supplements and methods of making and using them
US7361275B2 (en) * 2004-04-13 2008-04-22 Eastman Kodak Company Use of derivatized nanoparticles to minimize growth of micro-organisms in hot filled drinks
CN101868180A (zh) * 2007-10-09 2010-10-20 圣路易斯华盛顿州立大学 成像粒子
EP2161020A1 (en) * 2008-09-09 2010-03-10 Koninklijke Philips Electronics N.V. Chelating amphiphilic polymers
PT2550020E (pt) * 2010-03-24 2015-10-20 Medesis Pharma Microemulsão de micelas reversas compreendendo iões metálicos e sua utilização
ES2614115T3 (es) * 2010-03-24 2017-05-29 Medesis Pharma Sistema de micelas inversas que comprenden ácidos nucleicos y su uso
US9040091B2 (en) 2012-03-22 2015-05-26 Nanotherapeutics, Inc. Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles

Also Published As

Publication number Publication date
JP2017506249A (ja) 2017-03-02
WO2015124581A1 (en) 2015-08-27
KR20160135204A (ko) 2016-11-25
CN106163571A (zh) 2016-11-23
AU2015220878A1 (en) 2016-09-29
KR102392454B1 (ko) 2022-04-28
CA2939760C (en) 2022-05-31
EA037605B1 (ru) 2021-04-20
IL247253A0 (en) 2016-09-29
JP6649262B2 (ja) 2020-02-19
US20190192420A1 (en) 2019-06-27
IL247253B (en) 2020-11-30
CA2939760A1 (en) 2015-08-27
US20170035909A1 (en) 2017-02-09
CN106163571B (zh) 2020-10-16
EP3107580B1 (en) 2024-02-14
US10172954B2 (en) 2019-01-08
AU2015220878B2 (en) 2020-07-09
EP3107580A1 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
PH12017500802A1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
MA41265B1 (fr) Compositions pour administration de médicaments iléo-jéjunal.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
PH12014501560A1 (en) Carbamate compounds and of making and using same
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201690159A1 (ru) Способы и композиции для лечения рака
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MD20160007A2 (ru) Ингибиторы RORC2 и способы их применения
BR112015027477A2 (pt) método para tratamento de um transtorno de deglutição
EA201691660A1 (ru) Применение обратно-мицеллярных систем для осуществления доставки хелатирующих агентов радионуклидов и металлов
SA518391121B1 (ar) 18f مثبطات موسومة بواسطة (psma) في مستضد الغشاء الخاص بالبروستاتا واستخدامها كعوامل تصوير تشخيصي لحالات سرطان البروستاتا
MX2015012528A (es) Inhibidores macrociclicos de cinasa inducibles por sal.
MA49116A (fr) Compositions pharmaceutiques contenant de l'insuline
MX2015011359A (es) Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2).
MX2015012526A (es) Inhibodores macrociclicos de cinasa rip2.
MA34815B1 (fr) Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer
MX2017001625A (es) Metodo para la induccion de saciedad.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use